US Patent 9,327,114: Claim Scope, Patent Strength and Iontophoretic Drug-Delivery Landscape

US Patent 9,327,114 protects a self-contained, co-packaged iontophoretic delivery device in which electrodes, power-control circuitry, drug-containing conductive media, removable barriers, transfer rings and protective housing are packaged together before use. The strongest protection is directed to the combination of sealed drug reservoirs and electrodes that become electrically engaged after barrier removal. Claims 11, 12, 15 and 16 narrow the technology to triptan compounds, particularly sumatriptan.

The patent is closely associated with the Zecuity sumatriptan iontophoretic transdermal system developed by NuPathe and commercialized by Teva. The claims cover device architecture and treatment methods, rather than a new sumatriptan molecule.

What does US Patent 9,327,114 protect?

US 9,327,114 contains two principal independent device claims and four method claims.

Claim group	Claims	Primary subject matter
First device platform	1	Co-packaged, self-contained iontophoretic system with two electrodes, drug reservoir, barriers, transfer rings and housing
Device-dependent limitations	2-13	Barrier removal, deformable housing, battery, support layers, recesses, non-stick material, tabs, hydrogel, polyamide and triptan drug
General treatment method	14	Administering a drug with the claim 1 device
Triptan treatment	15	Treating a triptan-responsive condition
Sumatriptan treatment	16	Treating a triptan-responsive condition with sumatriptan
Second device platform	17	Co-packaged system organized into electrode, power-controller and therapeutic-compound regions
Second treatment method	18	Administering a drug with the claim 17 device

The patent does not broadly claim all iontophoresis. It requires a specific integrated package in which the device is supplied with the electrode components, conductive media, power controller and drug-containing reservoir in a protected housing.

How broad is independent claim 1?

Claim 1 is a combination claim with a high number of structural limitations. Its required elements include:

A first electrode and a second electrode.
An integrated power controller.
Circuitry connecting the electrodes to the controller.
A first conductive reservoir containing both a conductive medium and therapeutic compound.
A second conductive reservoir containing a conductive medium.
A removable barrier between the first electrode and first reservoir.
A second removable barrier between the second electrode and second reservoir.
Electrical contact created after removal of the barriers.
Transfer rings that affix and position the conductive media.
A removable protective housing.
A top housing portion coupled to a bottom housing portion.
A barrier portion that extends outside the housing.

The claim therefore covers more than an electrode patch with a battery. A potentially infringing product would need to satisfy the complete combination, either literally or under the doctrine of equivalents.

What is the central inventive concept?

The central concept is delayed activation of a prepackaged iontophoretic system. The conductive media and electrodes are kept physically separated during packaging and storage. The user removes an externally accessible barrier, allowing the conductive media to contact and adhere to the electrodes. The system can then be applied and activated without separately loading a drug reservoir or assembling electrode components.

The transfer rings are important. They maintain the position of the conductive media relative to the electrodes during use. A device using a different retention structure could create a claim-construction and infringement issue, depending on whether the alternative performs substantially the same function in substantially the same way.

What does claim 2 add?

Claim 2 requires that barrier removal occur while the electrodes, controller and conductive reservoirs remain inside the housing. This excludes systems in which the user removes a cartridge, opens the package and separately assembles the drug reservoir and electrode module.

What does claim 3 add?

Claim 3 requires a deformable top or bottom housing portion that can be pressed to bring the conductive medium into contact with the electrode after barrier removal. A rigid enclosure with automatic contact caused only by a spring, latch or sliding mechanism may fall outside the literal scope of this dependent claim, although claim 1 would remain separately relevant if its elements are met.

What do claims 4-10 add?

These claims cover implementation details:

Claim	Limitation
4	Battery inside the housing
5	Support layer for the controller and electrodes
6	Receiving layer with recesses for the conductive media
7	Non-stick portion of the removable barrier
8	External barrier tab
9	Hydrogel conductive medium
10	Polyamide conductive medium

Claims 9 and 10 are alternatives. A hydrogel formulation is not required by claim 1, but it is required for claim 9. A polyamide formulation is required for claim 10.

What protection is provided for sumatriptan and triptan compounds?

Claims 11 and 12 narrow claim 1 to a triptan compound and sumatriptan, respectively. Claims 15 and 16 protect treatment methods using the corresponding device configuration.

Claim	Protected therapeutic subject matter
11	Claim 1 system containing a triptan compound
12	Claim 1 system containing sumatriptan
15	Treating a triptan-responsive condition with a triptan using the claim 11 system
16	Treating a triptan-responsive condition with sumatriptan using the claim 12 system

The claims do not cover every sumatriptan dosage form. They require administration through the specified iontophoretic system. Conventional oral, intranasal, subcutaneous or passive transdermal sumatriptan products would not ordinarily satisfy these apparatus limitations.

The phrase “triptan responsive state” is functionally broad but remains tied to use of the claimed iontophoretic apparatus. The method claims may face separate issues concerning divided infringement, patient or physician conduct, induced infringement and proof that the required condition is being treated.

What does independent claim 17 cover?

Claim 17 is a second independent device claim. It reorganizes the claim 1 architecture into functional regions:

An electrode region with first and second electrodes.
A power-controller region.
Circuitry connecting the electrodes and controller.
A therapeutic-compound region containing conductive media.
A therapeutic compound in solution in the first conductive medium.
A protective housing substantially enclosing the system.
A removable barrier accessible from outside the housing.
Automatic adhesion and electrical contact after barrier removal.
First and second transfer rings.

Claim 17 omits several express limitations from claim 1, including the specific “top housing portion coupled to a bottom housing portion” language, the external barrier portion described as extending outside the housing, and the claim 1 wording concerning the first reservoir while the seal remains intact. This gives claim 17 a different infringement profile and may make it relevant to products that avoid the particular two-part housing structure of claim 1.

The word “substantially enclosing” may provide broader coverage than the more detailed housing language in claim 1. Its scope would depend on the specification, prosecution history and claim-construction record.

How strong is the patent estate for the claimed iontophoretic system?

The patent has meaningful commercial relevance because the claims combine several elements that are likely to be present in a commercial disposable iontophoretic patch. Its principal strengths are:

Protection of a complete ready-to-use package rather than a single material.
Coverage of barrier-controlled activation.
Coverage of internal batteries and integrated control circuitry.
Coverage of drug-containing conductive media.
Specific sumatriptan and triptan method claims.
A second independent apparatus claim with a different organizational structure.

Its principal weaknesses are:

Claim 1 is structurally dense.
Many limitations may have been individually known in iontophoresis, transdermal systems or medical packaging.
Prior art combining disposable electrodes, hydrogel reservoirs, batteries and peelable barriers could support an obviousness challenge.
The transfer-ring requirement may limit enforcement against products using alternative reservoir-retention structures.
Method claims depend on use of the claimed device and may be harder to enforce against upstream manufacturers that do not perform the treatment step.
The claims do not independently protect sumatriptan as a chemical entity or the general concept of iontophoretic delivery.

A validity assessment must examine the patent’s cited references, prosecution history, continuation practice and any inter partes review or litigation record. The claim text alone supports a preliminary scope analysis but does not establish validity or enforceability.

What patents protect Zecuity and related iontophoretic products?

Zecuity was a single-use iontophoretic transdermal system containing sumatriptan. The product was approved by the FDA under NDA 022254 in 2013 and was later withdrawn from the market after reports of application-site burns and scars. FDA classified the withdrawal as related to safety concerns rather than a failure of efficacy or manufacturing quality [2, 3].

The broader Zecuity patent estate included multiple patent families directed to:

Technology area	Typical protection
Iontophoretic delivery	Current-controlled transport of active ingredients through skin
Device architecture	Electrode arrangement, controller, battery and disposable patch construction
Drug reservoir	Hydrogels, conductive formulations and drug-containing media
Packaging and activation	Seals, peel tabs, separated reservoirs and activation steps
Therapeutic use	Transdermal administration of sumatriptan for migraine and related conditions
Manufacturing	Assembly, filling, sealing and integration of disposable components

US 9,327,114 is most significant for the co-packaged activation and reservoir-to-electrode architecture. It should be analyzed separately from earlier patents that may claim iontophoretic current control, electrode chemistry or sumatriptan delivery more generally.

What is the Orange Book status of US 9,327,114?

The Orange Book must be reviewed at the product and NDA level rather than by patent number alone. FDA patent listings are associated with an approved drug product and its NDA. A patent covering a delivery device is not automatically listed merely because the device administers an approved active ingredient.

For Zecuity, the relevant regulatory questions are:

Whether US 9,327,114 was submitted for NDA 022254.
Whether FDA accepted it as a listed patent.
Whether the listing was removed, expired or remained in the historical Orange Book record.
Whether any approved product currently relies on the patent.
Whether the patent claims the approved product, an approved method of use or only an unlisted device configuration.

Because Zecuity was withdrawn and is not an actively marketed U.S. product, the patent’s current commercial significance is materially lower than it would have been during the product’s launch period. Historical listing status remains relevant to freedom-to-operate and litigation analysis, but it does not create a current generic-launch barrier by itself [4].

When does US Patent 9,327,114 lose exclusivity?

A U.S. patent’s ordinary term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension and terminal disclaimers [5].

The relevant expiration date cannot be calculated from the claim text. The controlling record is the USPTO continuity data, including:

Earliest effective nonprovisional filing date.
Any provisional applications.
Continuation or divisional relationships.
Patent-term adjustment.
Terminal disclaimer status.
Patent-term extension under 35 U.S.C. § 156.

The patent issued in 2016. Its enforceability period therefore depends on the underlying filing chain rather than the issue date. A patent’s expiration also does not eliminate separate rights under related continuation patents, formulation patents, method-of-use patents or manufacturing patents.

Which companies could challenge or design around the patent?

The most relevant potential challengers would be companies developing disposable iontophoretic systems for migraine drugs, local anesthetics, peptides or other charged molecules. Potential commercial categories include:

Generic or hybrid-drug applicants for sumatriptan delivery systems.
Medical-device companies developing drug-device combination patches.
Contract manufacturers producing electrode and hydrogel assemblies.
Developers of iontophoretic delivery for non-triptan compounds.
Companies using reusable controllers with disposable reservoirs.
Companies using passive or microneedle-based transdermal delivery.

A product could reduce literal infringement risk by changing one or more required features:

Design-around approach	Potential claim effect
Keep reservoirs permanently attached to electrodes	Avoids the removable barrier and delayed-contact architecture
Use a removable cartridge outside the housing	May avoid the requirement that components remain inside the housing during barrier removal
Replace transfer rings with molded wells or adhesive films	May avoid the express transfer-ring limitation
Use one shared conductive medium or a different return-electrode structure	May avoid the first and second reservoir arrangement
Use a reusable controller	May avoid the self-contained single-use configuration
Activate through a latch, switch or spring	May avoid the deformable-housing limitation in claim 3
Use a non-sumatriptan active ingredient	Avoids claims 12 and 16 but not necessarily claims 1, 14 or 17
Use passive transdermal, oral, nasal or injectable delivery	Avoids the iontophoretic apparatus claims

Avoiding a dependent limitation does not avoid claim 1 or claim 17 unless the changed feature is required by the independent claim.

What Paragraph IV or litigation risks exist?

A generic applicant seeking approval for a product that relies on the same iontophoretic architecture could face a Paragraph IV certification if the patent were listed for the reference product and had not expired. The principal invalidity theories would likely include:

Anticipation based on earlier iontophoretic patches with separated electrodes and drug reservoirs.
Obviousness based on combining known iontophoretic devices with peelable packaging and hydrogel reservoirs.
Indefiniteness involving terms such as “configured to adhere,” “substantially enclosing” and “triptan responsive state.”
Written-description or enablement challenges if the claims reach broad classes of conductive media, therapeutic compounds or housing arrangements.
Noninfringement based on the absence of transfer rings, external barrier access or internal co-packaging.

No biosimilar pathway is relevant. Sumatriptan is a small-molecule active ingredient, and competing products would generally use an abbreviated new drug application or another drug-device regulatory pathway, not a biosimilar application.

The public commercial record most strongly associates the product with Teva’s withdrawal of Zecuity in 2016. That withdrawal reduced the immediate likelihood of a conventional generic challenge directed to an actively marketed reference product [3]. It does not eliminate potential disputes involving device copying, historical sales, reintroduction of a similar product or use of the architecture with another active ingredient.

How does US 9,327,114 compare with conventional transdermal patents?

Issue	US 9,327,114	Conventional passive patch patent
Delivery force	Electrically assisted iontophoresis	Diffusion through skin
Power source	Integrated controller and battery	Usually no battery
Reservoir activation	Delayed contact after barrier removal	Drug layer generally preassembled
Packaging	Co-packaged, self-contained housing	Standard sealed pouch or liner
Core claim focus	Device architecture and activation sequence	Drug matrix, adhesive, backing or permeation enhancer
Drug specificity	Broad in claims 1, 14 and 17; triptan-specific in claims 11, 12, 15 and 16	Often active-ingredient or formulation specific
Main design-around	Alter packaging, contact mechanism or retention structure	Alter matrix, adhesive or enhancer

The patent’s commercial value is concentrated in the integrated package and activation mechanism. It is less useful against products that deliver sumatriptan through unrelated routes.

Key Takeaways

US 9,327,114 claims a self-contained, single-use iontophoretic delivery package.
Claim 1 requires two electrodes, two conductive reservoirs, removable barriers, transfer rings and a protective housing.
Claim 17 provides a second independent apparatus route with region-based claim language.
Claims 11, 12, 15 and 16 target triptan and sumatriptan use.
The patent does not broadly cover all sumatriptan products or all iontophoretic devices.
The transfer rings, barrier configuration and internal co-packaging are the principal infringement choke points.
Zecuity is the principal commercial product associated with this technology.
FDA withdrawal of Zecuity reduced the patent’s immediate Orange Book and generic-entry significance.
No biosimilar pathway applies because sumatriptan is a small-molecule drug.
A current freedom-to-operate opinion requires review of the USPTO continuity record, patent-term data, Orange Book history, related patent families and litigation databases.

FAQs

Does US 9,327,114 cover a sumatriptan nasal spray?

No. Claims 12 and 16 require sumatriptan to be administered through the claimed iontophoretic delivery system.

Can a device infringe US 9,327,114 without using sumatriptan?

Yes. Claims 1, 14 and 17 are not limited to sumatriptan. Claims 11, 12, 15 and 16 contain the triptan or sumatriptan restrictions.

Are hydrogel reservoirs mandatory under the patent?

No. Hydrogel is required only by claim 9. The independent claims do not expressly require hydrogel.

Is the external pull tab alone enough to create infringement?

No. Claim 8 requires a tab, but infringement of claim 1 requires the complete combination of claim 1 elements. A tab by itself is not the claimed invention.

Does withdrawal of Zecuity invalidate US 9,327,114?

No. Product withdrawal does not itself invalidate a patent. It may reduce the patent’s commercial relevance and affect Orange Book or generic-entry analysis.

References

United States Patent and Trademark Office. (2016). U.S. Patent No. 9,327,114, self-contained co-packaged iontophoretic drug delivery system.
U.S. Food and Drug Administration. (2013). FDA approves new treatment for migraine headaches: Zecuity sumatriptan iontophoretic transdermal system.
U.S. Food and Drug Administration. (2016). FDA alerts patients and health care professionals about the voluntary withdrawal of Zecuity migraine patch.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension guidance.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y			METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011332187	⤷ Start Trial
Brazil	112013012117	⤷ Start Trial
Canada	2817824	⤷ Start Trial
China	103228318	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,327,114

Which drugs does patent 9,327,114 protect, and when does it expire?

Summary for Patent: 9,327,114